Successful treatment of feline leishmaniosis using a combination of allopurinol and N-methyl-glucamine antimoniate

Maria Alexandra Basso¹, Cátia Marques¹, Marcos Santos¹, Ana Duarte¹, Hugo Pissarra¹, L Miguel Carreira¹, Lídia Gomes¹, Ana Valério-Bolas², Luís Tavares¹, Gabriela Santos-Gomes² and Isabel Pereira da Fonseca¹

Abstract
Case summary This work describes the diagnosis and successful treatment of a 2-year-old domestic cat infected with Leishmania species and presenting fever, and ulcerative and nodular skin lesions after being treated for pyodermatitis for 1 year without clinical improvement. After anamnesis the cat was submitted to a complete clinical examination. Blood was collected for determination of haematological and biochemical parameters, detection of feline leukaemia virus (FeLV), feline immunodeficiency virus (FIV), feline coronavirus (FCoV) and Leishmania amastigotes. Fine-needle aspiration puncture from the skin nodules was also performed. After definitive diagnosis the animal was treated and followed up over a 2 year period. The animal tested negative for FIV-specific antibodies, FeLV antigen and feline coronavirus RNA. Leishmania amastigotes in the skin nodules were confirmed by cytology and molecular diagnosis. Treatment was initiated with allopurinol, resulting in a slight clinical improvement. Thus, N-methyl-glucamine antimoniate was added and administered for 30 days, with complete closure of the ulcerative lesions in the hindlimbs requiring a surgical approach. Close monitoring of the patient in the following 24 months indicated that combined therapy was safe and clinical cure was achieved without further relapses or side effects.

Relevance and novel information Considering the increasing number of feline leishmaniosis cases and the inconsistent results of most therapeutic protocols described in the literature, the use of new approaches, especially in refractory cases, is essential. Although the use of allopurinol and N-methyl-glucamine antimoniate is off-label in cats, in this case the combination treatment was followed by an extensive analytical monitoring, supporting their safety and effectiveness.

Accepted: 8 January

Introduction
The occurrence of feline leishmaniosis (FeL) has increased worldwide, revealing a possible role of cats in leishmaniosis epidemiology. Better accuracy of laboratory techniques has improved the diagnosis of this disease, and changes in ecosystems over the last few years associated with the use of repellents on dogs might play a role in sandflies’ altered feeding patterns in urban areas, leading to infections in other mammalian hosts.¹⁻³

¹Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal
²Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, New University of Lisbon, Lisbon, Portugal

Corresponding author: Isabel Pereira Fonseca DVM, PhD, Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Avenida da Universidade Técnica, 1300-477 Lisbon, Portugal
Email: ifonseca@fmv.ulisboa.pt

Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Worldwide epidemiological surveys of *Leishmania* species causing feline asymptomatic infection and FeL have been reported. In Europe, Spain had the first described FeL case in 1932. Some authors claim that low prevalence of FeL in endemic areas may be related to a natural resistance to the parasite in cats. Moreover, the number of clinical cases may be underestimated, leading to few reports and lack of information by clinicians and owners. Although Portugal is an endemic country for canine leishmaniosis caused by *Leishmania infantum*, there are few published clinical reports of FeL, with the first description of it in 1994 in Sesimbra, followed by others in Porto and Lisbon.

Despite occasional reports of ocular and visceral disease, dermatological, mucocutaneous/mucosal presentations and lymph node enlargement are the most frequent clinical features. Clinical suspicion is based on history, clinical signs and clinicopathological abnormalities. Diagnosis is confirmed with parasitological and serological methods.

A long-term administration of allopurinol (10–20 mg/kg q12h or q24h) is the most recommended treatment protocol for FeL, however, similarly to dogs, recurrence can occur if the infection is not cleared. Some authors have reported a good clinical response using N-methyl-glucamine antimoniate monotherapy (5–100 mg/kg or 375 mg/cat q24h SC or IM under different protocols).

This study aims to describe the treatment of a recurring clinical case of FeL in a cat receiving combined therapy (allopurinol and N-methyl-glucamine antimoniate).

**Case description**

A 2-year-old domestic European neutered male cat was referred to the Veterinary Teaching Hospital of the Faculty of Veterinary Medicine, University of Lisbon, with multiple nodular skin lesions (Figure 1), ulcerative dermatitis involving the four limbs (Figure 2) and fever. The cat was referred 1 year after the onset of skin lesions and was previously treated for a presumptive pyoderma with prednisolone (1 mg/kg PO q12h for 12 days) and amoxicillin/clavulanic acid (20 mg/kg PO q12h for 6 days), followed by doxycycline (5 mg/kg PO q12h for 8 days), and showed no clinical improvement.

The cat was not vaccinated, but had been regularly protected against ectoparasites with fipronil and imidacloprid. At first admission, mild fever (39.5°C) and dermatological lesions on the head and limbs were the only abnormalities on physical examination. About 20–25 skin nodules measuring 2–10 mm in diameter were distributed on the outer pinna surfaces and orbital regions (Figure 1a) and on the pinnae, where they gathered with coalescing patterns.

Differential diagnosis was pyoderma, allergic reaction, autoimmune disease, neoplastic disease or...
leishmaniosis. Single spots (20–50 mm in diameter) of ulcerative dermatitis, which had raised margins, affected the antebrachial (Figure 2a) and hock (Figure 2b) regions.

A complete blood count and biochemical profile were used to evaluate the clinical status of the cat before treatment, after treatment and at all follow-up examinations. Urinalysis and urinary protein: creatinine ratio were evaluated 6 months after treatment. Haematological and biochemical values were within the reference intervals. Serum protein electrophoresis showed an albumin: globulin ratio, but a slight hypergammaglobulinaemia was evident (Table 1).

The patient was tested for FIV-specific antibodies, FeLV antigens by ELISA (ViraCHEK/FIV and ViraCHEK/FeLV, respectively; Synbiotics) and immunofluorescence antibody test (IFAT) using an adaptation of *Leishmania* Spot IFI kit (bioMérieux) with a fluorescently labelled anticit IgG conjugate (anticat IgG MegaCor; MegaCor Diagnostik), which was used to quantify anti-*Leishmania* antibodies (cut-off 1:40). Previous studies, including more than 100 cats, validated this latter test in inter-laboratory assays using known positive and negative sera, with results as expected. Repeatability and reproducibility were also assessed (unpublished results). The cat tested negatively for FIV antibodies and FeLV antigens, but was positive for anti-*Leishmania* antibodies, with a titre ≥1:1280 (Table 1).

### Table 1 Haematological, biochemical and serological results obtained before, during and after treatment

|                         | Day 0 | Day 45 | Month 6 | Month 12 | Month 18 | Month 24 | Reference intervals |
|-------------------------|-------|--------|---------|----------|----------|----------|---------------------|
| **Haemogram**           |       |        |         |          |          |          |                     |
| Leukocytes (×10³/µl)    | 13.3  | 15.0   | 10.0    | NA       | NA       | 15.6     | 5.5–19.5            |
| Erythrocytes (×10⁶/µl)  | 6.6   | 9.2    | 10.2    | NA       | NA       | 9.5      | 5.0–10.0            |
| Platelets (×10⁹/µl)     | 185   | 327    | 129     | NA       | NA       | 223      | 300–700             |
| Haemoglobin (g/dl)      | 9     | 12     | 14      | NA       | NA       | 13       | 8–15                |
| PCV (%)                 | 29    | 40     | 40      | NA       | NA       | 43       | 24–45               |
| Non-segmented neutrophils (/µl) | 0   | 0      | 0       | NA       | NA       | 0        | 0–300               |
| Segmented neutrophils (/µl) | 9.520 | 11,000 | 6.468   | NA       | NA       | 7.000    | 2.500–12.500        |
| Lymphocytes (/µl)       | 2.856 | 3000   | 2.980   | NA       | NA       | 2.800    | 1.500–7.000         |
| Monocytes (/µl)         | 0.5   | 0.3    | 0.1     | NA       | NA       | 4.7      | 0–850.0             |
| Eosinophils (/µl)       | 0.680 | 0.600  | 0.390   | NA       | NA       | 0        | 0–1.500             |
| Basophils (/µl)         | 0     | 0      | 0       | NA       | NA       | 0        | Rare                |
| **Biochemical parameters** |     |        |         |          |          |          |                     |
| Urea (mg/dl)            | 48.7  | 52.9   | 50.0    | NA       | 52.3     | 59.9     | 0–82.0              |
| Creatinine (mg/dl)      | 0.73  | 0.97   | 1.07    | NA       | 1.23     | 1.25     | 0.70–2.20           |
| ALT (U/l)               | 37    | 37     | 35      | NA       | 45       | 37       | 10–130              |
| AST (U/l)               | NA    | NA     | NA      | 28       | 28       | 8–35     |                     |
| Alkaline phosphatase (U/l) | NA  | NA     | NA      | 9.52     | 8.92     | 9.40–11.20 |                     |
| Total bilirubin (mg/dl) | NA    | NA     | NA      | 0.06     | 0.05     | 0.08–0.30 |                     |
| Potassium (mmol/l)      | NA    | NA     | NA      | 4.4      | 4.8      | 3.5–5.2   |                     |
| Chloride (mmol/l)       | NA    | NA     | NA      | 123      | 137      | 108–128   |                     |
| Sodium (mmol/l)         | NA    | NA     | NA      | 156      | 156      | 143–153   |                     |
| Biliary acids (µmol/l)  | NA    | NA     | NA      | 3.68     | 3.53     | 1–20.00   |                     |
| Inorganic phosphorus (mmol/l) | NA | NA     | NA      | 4.4      | 4.8      | 2.4–6.0   |                     |
| Urinary protein: creatinine ratio (%) | NA | NA | 0.04 | NA | NA | <0.50 |                     |
| **Serum protein electrophoresis** |     |        |         |          |          |          |                     |
| Total protein (g/dl)    | 6.9   | 7.1    | 6.8     | NA       | 7.2      | NA       | 5.7–7.9            |
| Albumin (g/dl)          | 2.6   | 2.7    | 3.1     | NA       | 3.2      | NA       | 2.1–4.0            |
| Alpha 1 (g/dl)          | 0.4   | 0.1    | 0.1     | NA       | 0.1      | NA       | 0.2–1.1            |
| Alpha 2 (g/dl)          | 1.1   | 1.4    | 1.6     | NA       | 1.7      | NA       | 0.4–0.9            |
| Beta (g/dl)             | 0.4   | 1.1    | 0.9     | NA       | 1.1      | NA       | 0.9–1.9            |
| Gama (g/dl)             | 2.4   | 1.9    | 1.1     | NA       | 1.1      | NA       | 1.3–2.2            |
| Albumin: globulin ratio (%) | 0.60  | 0.60   | 0.90    | NA       | 0.80     | NA       | 0.45–1.30          |

*Table 1* Haematological, biochemical and serological results obtained before, during and after treatment

PCV = packed cell volume; ALT = alanine aminotransferase; AST = aspartate aminotransferase; NA = not available

Antibody titre (IFAT)

- Anti-*Leishmania* antibodies: ≥1:1280
Fine-needle aspiration puncture from the ear skin nodules was performed. Smears were stained with Giemsa (Merck) and examined under an optical microscope (Olympus BX51). The aspirate was also used for further molecular and parasitological analysis. The smears revealed *Leishmania* amastigotes (Figure 3), and absence of bacteria/neutrophilic infiltration or characteristic cells of autoimmune diseases.

DNA extraction from EDTA blood samples, skin nodules and lymph node aspirates was carried out with a DNeasy Blood & Tissue kit (Qiagen). Detection of feline coronavirus from plasma was performed by reverse transcription quantitative PCR (RT-qPCR), targeting the 3' end of the virus genome. Additionally, qPCR using *L. infantum*-specific Taqman probes targeting the kinetoplast minicircle DNA (kDNA) was also performed to determine the initial and follow-up parasitic load.17

RT-qPCR was negative for coronavirus, while qPCR of skin nodules and blood samples were positive for *L. infantum* kDNA, showing a parasitic load of 1700 and 0.1 parasites per 50 ng DNA, respectively (Table 2).

Nodular and lymph node aspirates were inoculated in Schneider’s Insect Medium (Sigma-Aldrich) supplemented with 0.6% (w/v) of CaCl₂, 5 mM Hepes, 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin.18 Cultures were maintained at 24°C in a refrigerated incubator (Lovibond) and observed by optical microscopy after 8 days of incubation. Viable promastigotes were observed.

The cat was treated orally with 10 mg/kg allopurinol q12h and a three-layered bandage was applied to the four limbs. Medical follow-up was performed every 2 days during the first fortnight. After 15 days of treatment with allopurinol only a slight clinical improvement was noted. Fever persisted and skin ulcers seemed equally profound. Therefore, a combined therapeutic protocol not yet approved for cats was suggested to the owner. N-methyl-glucamine antimoniate administration is off-label in cats, with only a few published cases of FeL treated with this drug. After owner consent was obtained, treatment was reinforced with 50 mg/kg N-methyl-glucamine antimoniate (Glucantime; Merial) q24h SC for 30 consecutive days. This study was conducted in the framework of FCT Project PTDC/CVT/118566/2010, with the agreement of the Ethics Committee and Animal Welfare of the Faculty of Veterinary Medicine, University of Lisbon.

During and after treatment there were no abnormalities reported by the owner. The cat maintained a normal physical condition19 and examination apart from the skin lesions.

Total remission of skin nodules on the head, as well as the foreleg ulcers, was achieved (Figure 4), with body temperature being normalised on day 45. Complete closure of the hindlimb ulcerative lesions did not occur owing to an extreme tension in those regions, which required surgery (Figure 5). One hour prior to surgery, the cat received a therapeutic protocol of Ringer’s lactate fluid therapy, amoxicillin with clavulanic acid (8.75 mg/kg IM), buprenorphine (0.02 mg/kg IM) and methylprednisolone succinate (1 mg/kg IM). Propofol (4 mg/kg IV) was used for the induction of anaesthesia followed by isoflurane for its maintenance. Debridement and excision of the wound edges were performed and a horizontal mattress suture was used for closure. The excised edges of the defect were immersed in a 10% formalin solution to allow for histopathological study.

The cat was medicated with antibiotic (amoxicillin/clavulanic acid, 12.5 mg/kg PO q12h for 10 days) and a non-steroidal anti-inflammatory (tolfenamic acid 4 mg/kg PO q 24h for 4 days), and was assessed 48 h after surgery in order to evaluate the regions operated on; stitches were removed on days 6 and 12. As an integral part of

| Table 2 *Leishmania infantum* parasitic load detected by quantitative PCR before, during and after treatment |
|------------------------------------------------------|
| Parasitic load (number of parasites/50 ng total DNA) |
| Day 0 | Day 30 | Day 45 | Month 18 |
| Skin nodules | 1700 | 10 | NA | NA |
| Blood | 0.10 | 0.05 | 0.05 | 0 |
| Lymph node | NA | 100.0 | 0.1 | 0 |

NA = not available
the healing process, the cat was maintained for 2 weeks with Robert-Jones bandages. The complete healing of hindlimb lesions was achieved 1 month after surgery (Figure 6).

Histological examination of the removed tissues showed a granulomatous-like inflammatory response with some foci of lymphocytes, activated plasmacytes and occasional intracellular amastigote forms of *Leishmania* species in macrophages.

The slight hypergammaglobulinaemia observed at admission returned to normal values. No further clinical or laboratory changes were detected 6, 18 and 24 months after the end of treatment (Table 1). Allopurinol was stopped when antibody titres decreased to 1:40 (18 months). At month 24, the antibody level remained unchanged.

Parasitic load decreased in both blood and skin nodules after 15 days of combined treatment. The lymph node parasitic load showed a pronounced decrease after day 30 (Table 2).

**Discussion**

FeL is rarely reported in various parts of the world.\(^4,20,21\)

In Europe, a total of 46 clinical cases have been published between 1989 and 2014, namely in Italy, France, Spain and Switzerland, with regards to cats imported from Spain.\(^4,20,22–24\) In Portugal, although the first clinical case was reported in the 1990s,\(^9\) only in recent years have epidemiological studies been conducted to better understand the role of cats in the biological cycle of *Leishmania* species. In the metropolitan region of Lisbon, although the detection of anti-*Leishmania* antibody titres points to

---

**Figure 4** Cat 18 months after treatment with allopurinol and N-methyl-glucamine antimoniate (Glucantime; Merial), illustrating the absence of skin nodules on the ears and head

**Figure 5** Intraoperative images showing the excision of the defect edges in the (a) right and (b) left hindlimb
weeks of the combined protocol the decrease in antibody titre and parasitic load was evident. Similarly to canine leishmaniosis, there was a gradual decline in antibody titre and it took around 18 months to attain the lowest titre. Clinical remission was accomplished together with surgical recovery in less than 2 months. Furthermore, this therapeutic protocol seemed to be safe for the cat as no analytical change or side effect was observed.

By 24 months of follow-up, no relapses had occurred. Regarding the albumin levels, although within the reference interval, the increase noted, associated with the decrease in gamma(γ)-globulin values, kept the total protein concentration within the reference interval, which is in agreement with the remission of clinical signs.

Cats may live for years with a slowly progressing chronic disease, even without a specific anti-Leishmania treatment.4,5,15 However, in this case, the severity of cutaneous lesions was the clinician’s main concern leading her to search for another therapeutic protocol when monotherapy with allopurinol proved to be insufficient.

Although full clinical recovery was achieved, it is possible that a much reduced number of viable parasites may have persisted (mainly in the lymph nodes) after the end of the treatment. However, as it is not possible to guarantee total elimination or its dispersion to the skin, parasite transmission should be kept in mind. These facts highlight the need for new topical insecticides aiming to prevent sandfly bites in cats, as all insecticide products currently registered against sandflies contain permethrin, which is extremely toxic to cats.

Conclusions
The present work describes a successful case of FeL treatment in a young cat, negative for FIV antibodies and FeLV antigenaemia, after a 15 day refractory period using allopurinol monotherapy. To the best of our knowledge, this is the first report of a combined therapy, using allopurinol and N-methyl-glucamine antimoniate with no relapses or adverse effects, resulting in a possible new treatment for use in FeL refractory cases.

Acknowledgements
We thank Merial (Portugal) for supplying the Glucantime used during the cat’s treatment.

Conflict of interest
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
Funding for this work was provided by the Portuguese Foundation for Science and Technology (FCT) with co-participation of European Union Fund (FEDER) through the research project PTDC/CVT/118566/2010 and UID/CVT/00276/2013, and grants SFRH/BD/77886/2011 and SFRH/BD/101467/2014.
References

1. WHO. Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. WHO Technical Report Series, 2010, p 186.
2. Campino L and Maia C. Epidemiologia das leishmanioses em Portugal. Acta Med Port 2010, 23: 859–864.
3. Maia C, Gomes J, Cristóvão J, et al. Feline Leishmania infection in a canine leishmaniasis endemic region, Portugal. Vet Parasitol 2010; 174: 336–340.
4. Pennisi MG, Cardoso L, Baneth G, et al. LeishVet update and recommendations on feline leishmaniosis. Parasit Vectors 2015; 8: 302.
5. Soares CSA, Duarte SC and Sousa SR. What do we know about feline leishmaniosis? J Feline Med Surg. Epub ahead of print 26 June 2015. DOI: 10.1177/1098612X15589358.
6. Ayllon T, Tesouro MA, Amusategui I, et al. Serologic and molecular evaluation of Leishmania infantum in cats from Central Spain. Ann NY Acad Sci 2008; 1149: 361–364.
7. Solano-Gallego L, Rodríguez-Cortés A, Iniesta L, et al. Cross-sectional serosurvey of feline leishmaniasis in ecoregions around the northwestern Mediterranean. Am J Trop Med Hyg 2007; 76: 676–680.
8. Costa-Durão J, Rebelo E, Peleteiro M, et al. First case of leishmaniosis in domestic cat (Felis catus domesticus) detected in Portugal (Sesimbra). Rev Port Cienc Vet 1994; 511: 140–144.
9. Maia C, Sousa C, Ramos C, et al. First case of leishmaniosis caused by Leishmania infantum genotype E in a cat with a concurrent nasal squamous cell carcinoma. J Feline Med Surg Open Rep 2015; 1 (2). DOI: 10.1177/2055169115593960.
10. Marcos R, Santos M, Malhão F, et al. Pancytopenia in a cat with visceral leishmaniasis. Vet Clin Path 2009; 38: 201–205.
11. Leiva M, Lloret A, Peña T, et al. Therapy of ocular and visceral leishmaniasis in a cat. Vet Ophthalmol 2005; 8: 71–75.
12. Verneuil M. Ocular leishmaniasis in a cat: case report. J Fr Ophthalmol 2013; 36: e67–e72.
13. Pennisi M, Venza M, Reale S, et al. Case report of leishmaniasis in four cats. Vet Res Commun 2004; 28: 363–366.
14. Simões-Mattos L, Bevilaqua C, Mattos M, et al. Feline leishmaniasis: uncommon or unknown? Rev Port Cienc Vet 2004; 9: 79–97.
15. Pennisi MG, Hartmann K, Lloret A, et al. Leishmaniosis in cats: ABCD guidelines on prevention and management. J Feline Med Surg 2013; 15: 638.
16. Gil S, Leal RO, Duarte A, et al. Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter. Res Vet Sci 2013; 94: 753–763.
17. Helbazar M, Leitão J, Duarte A, et al. Natural infection of synanthropic rodent species Mus musculus and Ratus norvegicus by Leishmania infantum in Sesimbra and Sintra – Portugal. Parasit Vectors 2013; 6: 88.
18. Hockmeyer WT, Kager PA, Rees PH, et al. The culture of Leishmania donovani in Schneider’s insect medium: its value in the diagnosis and management of patients with visceral leishmaniasis. Trans R Soc Trop Med Hyg 1981; 75: 861–863.
19. Bjornvad CR and Laflamme DP. Cat body condition score. http://www.wsava.org/sites/default/files/Body%20condition%20score%20chart%20cats.pdf (2013, accessed August 2, 2015).
20. Ozon C, Marty P, Pratlong F, et al. Disseminated feline leishmaniosis due to Leishmania infantum in Southern France. Vet Parasitol 1998; 75: 273–277.
21. Rougeron V, Catzeflis F, Hide M, et al. First clinical case of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis in a domestic cat from French Guiana. Vet Parasitol 2011; 181: 325–328.
22. Poli A, Abramo F, Barsotti P, et al. Feline leishmaniosis due to Leishmania infantum in Italy. Vet Parasitol 2002; 106: 181–191.
23. Rüfenacht S, Sager H, Müller N, et al. Two cases of feline leishmaniosis in Switzerland. Vet Rec 2005; 156: 542–545.
24. Pennisi M. Feline leishmaniosis from A to Z [in Italian]. In: Veterinarie E (ed). Leishmaniosi canina: recenti acquisizioni su pidemiologia, implicazioni cliniche, diagnosi, terapia e prevenzione. Cremona: Edizioni Veterinarie, 2010, pp 59–64.
25. Hervás J, Chacón-Manrique de Lara F, Sanchez-Isarria M, et al. Two cases of feline visceral and cutaneous leishmaniosis in Spain. J Feline Med Surg 1999; 1: 101–105.
26. Pennisi MG, Lupo T, Malara D, et al. Serological and molecular prevalence of Leishmania infantum infection in cats from southern Italy. J Feline Med Surg 2012; 14: 656–657.